your market intelligence analyst
Search Results
Edit Save
2,369 results
Onclive 12/05/2019 16:21
The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for December 17, 2019, to discuss a supplemental new drug application for olaparib tablets as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA -mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.
Onclive 12/05/2019 12:53
During a recent OncLive Peer Exchange , a panel of leukemia and lymphoma experts discussed 2 emerging BTK inhibitors: acalabrutinib, which was approved in October 2017 for previously treated mantle cell lymphoma (MCL) and received a breakthrough therapy designation in August 2019 for chronic lymphocytic leukemia, and zanubrutinib, which was approved in November for patients with MCL who have received at least 1 prior therapy.

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities


Strategic Scenarios